Clinical Effects of the Immunization Protocol UsingLoxosceles Venom in Naïve Horses
- PMID:35622586
- PMCID: PMC9148105
- DOI: 10.3390/toxins14050338
Clinical Effects of the Immunization Protocol UsingLoxosceles Venom in Naïve Horses
Abstract
Bites of brown spiders (Loxosceles spp.) are responsible for dermonecrotic lesions and potentially systemic envenoming that can lead to death. The only effective therapy is the use of the antivenom, usually produced in horses. However, little is known about the consequences of the systematic use of theLoxosceles venom and adjuvants and of the bleedings on antivenom-producing horses. Thus, the aim of this study was to evaluate the clinical changes in horses in their first immunization protocol forLoxosceles antivenom production. Eleven healthy horses, never immunized, were evaluated in three different periods: T0 (before immunization); T1 (after their first venom immunization); and T2 (after their first bleeding). Horses were clinically evaluated, sampled for blood, and underwent electrocardiographic (ECG) recordings. Several suppurated subcutaneous abscesses occurred due to the use of Freund's adjuvants and thrombophlebitis due to systematic venipunctures for the bleeding procedures. ECG showed arrhythmias in few horses in T2, such as an increase in T and R waves. In summary, the immunization protocol impacted on horses' health, especially after bleeding for antivenom procurement.
Keywords: antisera production; brown spider; dermonecrosis; loxoscelism; safety evaluation.
Conflict of interest statement
The authors declare no conflict of interest.
Figures



Similar articles
- A reduced immunization scheme to obtain an experimental anti-Loxosceles laeta ("violinist spider") venom.de Roodt AR, Litwin S, Dokmetjian JC, Vidal JC.de Roodt AR, et al.J Nat Toxins. 2002 Aug;11(3):193-203.J Nat Toxins. 2002.PMID:12182539
- Innovative immunization protocols using chimeric recombinant protein for the production of polyspecific loxoscelic antivenom in horses.Figueiredo LF, Dias-Lopes C, Alvarenga LM, Mendes TM, Machado-de-Ávila RA, McCormack J, Minozzo JC, Kalapothakis E, Chávez-Olórtegui C.Figueiredo LF, et al.Toxicon. 2014 Aug;86:59-67. doi: 10.1016/j.toxicon.2014.05.007. Epub 2014 May 28.Toxicon. 2014.PMID:24878371
- Cutaneous loxoscelism caused by Loxosceles similis venom and neutralization capacity of its specific antivenom.Chatzaki M, Horta CC, Almeida MO, Pereira NB, Mendes TM, Dias-Lopes C, Guimarães G, Moro L, Chávez-Olórtegui C, Horta MC, Kalapothakis E.Chatzaki M, et al.Toxicon. 2012 Jul;60(1):21-30. doi: 10.1016/j.toxicon.2012.03.007. Epub 2012 Mar 21.Toxicon. 2012.PMID:22465492
- History, challenges and perspectives on Loxosceles (brown spiders) antivenom production in Brazil.Miranda ALS, Guerra-Duarte C, Lima SA, Chávez-Olórtegui C, Soto-Blanco B.Miranda ALS, et al.Toxicon. 2021 Mar;192:40-45. doi: 10.1016/j.toxicon.2021.01.004. Epub 2021 Jan 16.Toxicon. 2021.PMID:33465358Review.
- The efficacy of antivenom in loxoscelism treatment.Pauli I, Puka J, Gubert IC, Minozzo JC.Pauli I, et al.Toxicon. 2006 Aug;48(2):123-37. doi: 10.1016/j.toxicon.2006.05.005. Epub 2006 Jun 30.Toxicon. 2006.PMID:16808942Review.
Cited by
- The Health Status of Horses Used for at Least Six Complete Cycles of Loxoscelic Antivenom Production.Miranda ALS, Antunes BC, Minozzo JC, Lima SA, Botelho AFM, Campos MTG, Chávez-Olórtegui C, Soto-Blanco B.Miranda ALS, et al.Toxins (Basel). 2023 Sep 26;15(10):589. doi: 10.3390/toxins15100589.Toxins (Basel). 2023.PMID:37888620Free PMC article.
References
- Chaim O.M., Trevisan-Silva D., Chaves-Moreira D., Wille A.C., Ferrer V.P., Matsubara F.H., Mangili O.C., da Silveira R.B., Gremski L.H., Gremski W., et al. Brown spider (Loxosceles genus) venom toxins: Tools for biological purposes. Toxins. 2011;3:309–344. doi: 10.3390/toxins3030309. - DOI - PMC - PubMed
- Martins G.C., Melo M.M., Soto-Blanco B. Araneísmo. Cad. Técnicos Veterinária E Zootec. 2014;75:61–70.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Miscellaneous